Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Cosmo Daisey who wrote (2077)	1/27/1998 5:55:00 PM
From: Dr. Voodoo	Respond to of 7041

Dr. Daisey, I have heard much about the Italian study, most of it cracks me up. I would agree that the endpoint in Zonagen's studies is subjective. I am still dealing with simpler issues. Blood levels for instance. Blood levels show that somebody at least might have attemped a PK study. Blood levels are an accepted measurement, and a cornerstone for Asensio and Zonagen to make their assertions. My guess originally was that both sides would have data to back up their claims, so far this has been true. And before you say it I will, blood levels may have nothing to do with the clinical results--which I don't disagree with. Both sides say they do, hence I think it's a good red herring to start with. There is alot of gray in all of this. For instance, in the J of Chromatography article, they mentioned that they had been using their method since 1974. Someone pointed out yesterday that at the Phentolamine Workshop(London-1975), GC was used as the method of analysis. I will have to go fetch the text of this workshop. Keep in mind just because someone doesn't publish a method in a peer reviewed journal doesn't always mean that it isn't valid. Rob